This phase I/II clinical trial investigates the safety and optimal dosage of Liposomal Cytarabine and Daunorubicin (CPX-351) combined with Quizartinib for individuals with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (HR-MDS). The study aims to determine the maximum tolerable dose of CPX-351, a formulation containing chemotherapy drugs daunorubicin and cytarabine, which function by killing cancer cells, preventing cell division, and inhibiting cell spread. Quizartinib, administered orally, may inhibit tumor cell growth by blocking specific enzymes involved in cell proliferation. The trial enrolls 52 participants with conditions including newly diagnosed or relapsed refractory AML and HR-MDS. Patients receive CPX-351 intravenously over 90 minutes on days 1, 3, and 5, alongside quizartinib orally on days 6-19. Treatment cycles consist of an induction phase, a consolidation phase, and a maintenance phase, repeating every 28 days for up to two cycles unless disease progression or unacceptable toxicity occurs. The primary objectives include determining the MTD of CPX-351 and quizartinib, and measuring the overall response rate (ORR) encompassing complete remission (CR), complete remission with incomplete platelet recovery (CRp), complete remission with incomplete count recovery (CRi), and partial remission (PR) within three months. Secondary objectives involve assessing overall survival (OS), event-free survival (EFS), and duration of response (DOR). Exploratory objectives include evaluating the ORR, EFS, and OS in patients with FLT3 mutated/NPM1 wild-type versus other FLT3 mutated/NPM1 mutated patient subgroups. The study also investigates quantitative changes in FLT3-ITD allelic burden and longitudinal evaluation of mutations over time. Furthermore, the trial assesses the impact of the treatment combination on patients transitioning to hematopoietic stem cell transplant (HSCT) and includes the collection of surplus blood or tissue for potential future research into factors influencing AML development and treatment response. Patient follow-up extends to 30 days, then every 3-6 months for up to 5 years.